- Agile Therapeutics continues to trade under intense selling pressure. This selling amplified after the company announced a sizeable offering.
- My "house money" position has been mostly sitting on the sidelines waiting for a capitulation and "max pain" event. I discuss my strategy for taking advantage of these opportunities.
- Agile is launching Twirla right into strong COVID-19 headwinds. I don't expect the company to report outstanding earnings until the pandemic subsides.
- It looks as if the market is waiting for calmer waters and a clear heading before it supports AGRX. Bulls need to know when to stay the course or jump ship.
For further details see:
Agile Therapeutics: Bullish On Capitulation And Max Pain